Fundz

NGM Bio raises $122M in Series A funding led by The Column Group for registrational PSC study and Phase II trial

PRIVATEJul 17, 2024

Amount Raised

$122 Million

Round Type

Series A

San FranciscoBiotechnologyHealth CareTherapeutics

Investors

The Column Group

Description

After completing a take-private transaction, NGM Bio announced a $122 million Series A financing led by its buyer, The Column Group. The funding will support a registrational study and a Phase II trial for aldafermin in patients with primary sclerosing cholangitis and a Phase II study of NGM120 for hyperemesis gravidarum.

Quick answer

NGM Bio raised $122 Million in a Series A round, dated July 17, 2024. Investors: The Column Group. NGM Bio is based in San Francisco, California, United States.

How much did NGM Bio raise?
NGM Bio raised $122 Million in a Series A round on July 17, 2024.
Who invested in NGM Bio?
The Column Group is named as investors in this round.
What does NGM Bio do?
NGM Bio is a biotech company focused on developing innovative therapies for serious, rare conditions with significant unmet patient needs.
Where is NGM Bio based and how big is it?
NGM Bio is based in San Francisco, California, United States. Fundz records about 169 employees.
Who are the decision-makers at NGM Bio?
Fundz holds 1 contact at NGM Bio. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who to call at NGM Bio, and when

A new round usually means NGM Bio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day NGM Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at NGM Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at NGM Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

NGM Bio

Location

San Francisco, California, United States

About

NGM Bio is a biotech company focused on developing innovative therapies for serious, rare conditions with significant unmet patient needs. The company aims to address underlying biological mechanisms of diseases such as primary sclerosing cholangitis (PSC) and hyperemesis gravidarum (HG) to provide potential treatment options. NGM Bio is committed to advancing clinical development efforts to benefit patients with rare conditions.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment NGM Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for NGM Bio's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

NGM Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.